Martin Mackay to lead AstraZeneca's R&D organisation
This article was originally published in Scrip
Executive Summary
AstraZeneca has appointed Martin Mackay to the newly created position of president of R&D, effective 1 July. He will lead the company's R&D organisation and will be responsible for delivering new products – small molecules and biologics – from AstraZeneca's pipeline.